Search
Arbutus Biopharma Corp
ABUSAdd to Watchlist
4.700USD
+0.030+0.64%
Close 08-14 16:00（ET）Quotes delayed by 15 min
928.88MMarket Cap
5.67P/E TTM
Forecast
Currency: USD Updated: 2026-08-14The current earnings forecast score of Arbutus Biopharma Corp is 8.67, ranking 75 out of 387 in the Biotechnology & Medical Research industry. The average price target is 5.00, with a high of 7.00 and a low of 5.00.
Analyst Rating
Based on
2
analysts
Strong Buy
Current Rating
5.500
Target Price
+17.77%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Arbutus Biopharma Corp
ABUS
2
Beigene Ltd
ONC
28
argenx SE
ARGX
28
Ionis Pharmaceuticals Inc
IONS
25
IQVIA Holdings Inc
IQV
24
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Arbutus Biopharma Corp's expected revenue for the next quarter?
Arbutus Biopharma Corp's expected revenue is 681.00K.
What is Arbutus Biopharma Corp's price target?
Analysts forecast that Arbutus Biopharma Corp's price target is USD 5.00, with the highest forecast at USD 7.00 and the lowest forecast at USD 5.00.
How have Arbutus Biopharma CorpABUS's recent earnings per share performed?
The market expectation was USD -0.03, while Arbutus Biopharma CorpABUS's earnings per share (EPS) for the previous quarter was USD 0.88. EPS for the next quarter is expected at USD -0.02.
What is the analyst rating for Arbutus Biopharma Corp?
Based on the ratings of Arbutus Biopharma Corp's stock from 2 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.